John W. Smither
CIK: 0001559583
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Sep 4, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct1.6K shares at avg. $25.32$41K - Aug 3, 2026MBX
MBX Biosciences, Inc.
Award(A)Direct28K shares- - Jul 1, 2026GNLX
GENELUX Corp
Sale(S)Direct12K shares at avg. $2.91$35K - Jun 16, 2026GNLX
GENELUX Corp
Award(A)Direct28.4K shares- - Jan 7, 2026NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct3.4K shares- - Aug 27, 2025GNLX
GENELUX Corp
Award(A)Direct22.3K shares- - Jan 7, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct7K shares- - Jan 6, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)DirectOption (right to buy)
32.5K shares- - Aug 1, 2024GNLX
GENELUX Corp
Award(A)DirectStock Option Right to Buy)
50.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 4, 2026 |  NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 1,600 | $25.32 | $40,512 | Direct |
| Aug 3, 2026 |  MBX MBX Biosciences, Inc. | Award(A) | 28,000 | - | $0 | Direct |
| Jul 1, 2026 |  GNLX GENELUX Corp | Sale(S) | 12,000 | $2.91 | $34,898 | Direct |
| Jun 16, 2026 | GNLX GENELUX Corp | Award(A) | 28,409 | - | $0 | Direct |
| Jan 7, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 3,400 | - | $0 | Direct |
| Aug 27, 2025 | GNLX GENELUX Corp | Award(A) | 22,283 | - | - | Direct |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 6,960 | - | $0 | Direct |
| Jan 6, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) Option (right to buy) | 32,500 | - | - | Direct |
| Aug 1, 2024 | GNLX GENELUX Corp | Award(A) Stock Option Right to Buy) | 50,469 | - | - | Direct |
1-9 of 9 transactions
About Smither John W
Smither John W (SEC CIK 0001559583) files insider reports with the SEC as Director of NewAmsterdam Pharma Co N.V. (NAMS), Director of Attovia Therapeutics, Inc. (ATTO) and Chief Financial Officer of MBX Biosciences, Inc. (MBX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 10 ownership filings by Smither John W (2 Form 3, 8 Form 4), filed between Dec 31, 2024 and Sep 9, 2026. Those filings report 9 transactions, from Aug 1, 2024 to Sep 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smither John W's filings is in NAARDEN.
Recent filings by Smither John W
- Sep 4, 2026: Open-market sale of NAMS shares (Form 4, code S).
- Aug 3, 2026: Grant or award of MBX shares (Form 4, code A).
- Jul 1, 2026: Open-market sale of GNLX shares (Form 4, code S).
- Jun 16, 2026: Grant or award of GNLX shares (Form 4, code A).
- Jan 7, 2026: Grant or award of NAMS shares (Form 4, code A).
Other insiders filing for NewAmsterdam Pharma Co N.V. (NAMS)
- Kastelein Johannes Jacob Pieter, Chief Scientific Officer
- Davidson Michael H., Chief Executive Officer
- Gunning Robert William, Vice President, Controller
- Kooij Louise Frederika, Chief Accounting Officer
- LANGE LOUIS G, Director
- Somaiya Mayur Ian, Chief Financial Officer